EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated transcriptomic analysis reveals a CEBPB–DUSP1 axis driving tumor progression in colorectal cancer

Huarong Zhou, Lili Fang iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0337892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Huarong Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Zhejiang Provincial Hospital of Dermatology, Deqing County, Zhejiang Province, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, CCAAT-Enhancer-Binding Protein-beta, Dual Specificity Phosphatase 1, Transcriptome. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a prevalent and lethal malignancy, yet the transcriptional networks driving its progression remain incompletely defined. Here, we used integrated transcriptomic analyses of healthy and colorectal cancer samples from three datasets—TCGA-COAD, GSE100179 and GSE196006, and laboratory assays to uncover CCAAT/enhancer-binding protein beta (CEBPB) as a key driver of CRC. Elevated CEBPB expression in clinical samples correlated with shorter overall survival, suggesting its utility as a prognostic marker. We next identified DUSP1, a dual specificity phosphatase critical for MAPK regulation, as a direct transcriptional target of CEBPB. Motif enrichment and promoter scans revealed three high-affinity CEBPB-binding sites in the DUSP1 promoter. Luciferase reporter assays confirmed that CEBPB directly modulates DUSP1 transcription. Knockdown of CEBPB in HCT116 cells rescued DUSP1 expression and reduced pro-tumor pathways linked to hyperactive MAPK. The resulting phenotype showed decreased cell proliferation, enhanced apoptosis, and partial reversion of the malignant features typically associated with CRC. These findings underscore that CEBPB–DUSP1 dysregulation contributes to CRC aggressiveness, influencing both inflammatory and metabolic processes. Overall, this work highlights CEBPB as a potential biomarker for poor prognosis and points to the CEBPB–DUSP1 axis as a promising therapeutic target. Our findings also demonstrate the power of integrated transcriptomic approaches in elucidating intricate gene regulatory networks, offering a basis for new strategies to mitigate CRC progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCCAAT-Enhancer-Binding Protein-betaDual Specificity Phosphatase 1TranscriptomeHumansGene Expression Regulation, NeoplasticDisease ProgressionGene Expression ProfilingCell ProliferationHCT116 CellsCell Line, TumorApoptosisPrognosisPromoter Regions, GeneticBiomarkers, Tumor

Substanzen

CCAAT-Enhancer-Binding Protein-betaCEBPB protein, humanDual Specificity Phosphatase 1DUSP1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Zhejiang Provincial Hospital of Dermatology, Deqing County, Zhejiang Province, China.
  • Department of Nursing, Zhejiang Provincial Hospital of Dermatology, Deqing County, Zhejiang Province, China.

ORCID-Profile: Lili Fang

Zitieren

APA

Zhou, H., & Fang, L. (2025). Integrated transcriptomic analysis reveals a CEBPB–DUSP1 axis driving tumor progression in colorectal cancer. PLOS One. https://doi.org/10.1371/journal.pone.0337892

Vancouver

Zhou H, Fang L. Integrated transcriptomic analysis reveals a CEBPB–DUSP1 axis driving tumor progression in colorectal cancer. PLOS One. 2025. doi:10.1371/journal.pone.0337892

BibTeX
@article{Zhou2025,
  author = {Zhou, Huarong and Fang, Lili},
  title = {Integrated transcriptomic analysis reveals a CEBPB–DUSP1 axis driving tumor progression in colorectal cancer},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0337892}
}
Kostenlos starten →